Skip to content

Evaluation of Sodium Pentaborate Topical Ointment on Hemorrhoid Symptoms

Evaluation of Sodium Pentaborate Topical Ointment on Hemorrhoid Symptoms

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190701044062N1
Enrollment
53
Registered
2019-07-13
Start date
2019-06-04
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoid. Hemorrhoids and perianal venous thrombosis

Interventions

Intervention 1: Intervention group: 3% sodium pentahydrate Phenytoinate gel twice daily for 1 month. Intervention 2: Control group: Treating patients with hemorrhoids in a way other than the mentioned

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 65-18 years old Patients with hemorrhoids and those with I, II, III or IV internal hemorrhoid disorder without need for emergency interventions based on physical examination The presence of anal bleeding as one of the symptoms of a hemorrhoid in the patient (according to the Sodergren scoring system) Non-use of a drug other than the drug and control drug for the treatment of hemorrhoids during the study period

Exclusion criteria

Exclusion criteria: Disorders and analgesics including inflammatory bowel disease, Fisher, fistula and perianal rash, rectal prolapse, rectus, benign or malignant tumor of the anus and rectum, and perianal infections Patients with sodium phentetrazur susceptibility or a history of skin sensitivity to vaseline Pregnancy or breastfeeding Patients with severe heart disease, neurology, liver and kidney disease and blood diseases Taking any local analgesic for the past 7 days Prohibition of topical use of vaseline or sodium panteurate The history of permanent prolapse is the entire thickness of the rectum

Design outcomes

Primary

MeasureTime frame
Severe itching. Timepoint: 25 to 30 days. Method of measurement: questionnaire and Sodergren Scoring System.;Severity of pain during rest. Timepoint: 25 to 30 days. Method of measurement: Severity of pain during rest.;Pain intensity when starting fecal excretion. Timepoint: 25 to 30 days. Method of measurement: Pain intensity when starting fecal excretion.;Frequent feeling of mass in the anus. Timepoint: 25 to 30 days. Method of measurement: Frequent feeling of mass in the anus.;The severity of the outgrowth of the hemorrhoid mass. Timepoint: 25 to 30 days. Method of measurement: Clinical evaluation.;The degree of anoscopic hemorrhoids. Timepoint: 25 to 30 days. Method of measurement: Clinical evaluation.;Number of hemorrhoid hemorrhages. Timepoint: 25 to 30 days. Method of measurement: Clinical evaluation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManouchehr Khoshbaten

Tabriz University of Medical Sciences

mkhoshbaten@yahoo.com+98 41 3335 9680

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026